Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07686393 · ClinicalTrials.gov registry record · Phase 1

PET Imaging of Noradrenergic Transmission in the Brain

A Phase 1 study, sponsored by National Institute of Mental Health (NIMH).

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target

NCT07686393 is a Phase 1 study that is actively recruiting participants, run by National Institute of Mental Health (NIMH). The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07686393, a Phase 1 study, is actively recruiting participants, sponsored by National Institute of Mental Health (NIMH).

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

Background: Researchers have developed a new radioactive tracer (11C-ARMI). A tracer is a drug that attaches itself to other chemicals in the body and lights up so that the chemicals can be seen in imaging scans. The new tracer may be able to help them with many diseases, such as Alzheimer s disease and Parkinson s disease. Researchers want to test the new tracer in healthy people. Objective: To test a new tracer (11C-ARMI) during imaging scans of the brain and body in healthy people. Eligibility: Healthy people aged 18 years and older. They must have been screened under protocols 01-M-0254 or 17M0181. Design: All participants will have a positron emission tomography (PET)/computed tomography (CT) scan. Before the scan, they will have blood and urine tests and a test of their heart function. The tracer will be given through a tube attached to a needle inserted into a vein in the arm. They will lie on a padded bed that fits inside a doughnut-shaped machine; the machine uses x-rays to create images of the inside of the body. Some participants will have a PET/CT scan of their whole body. They will need only 1 visit. Some participants will have a PET/CT scan of only their brain. They will have up to 2 visits. On the second visit, they will have a magnetic resonance imaging (MRI) scan of the brain. For the MRI, they will lie on a table that slides into a cylinder. The MRI uses magnetic fields to create images of the inside of the body. Participants will receive a follow-up call to check on their well-being after their PET/CT scans.

Interventions

  • DRUG 11C-ARMI

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-07-15
Est. Completion 2030-02-20
Phase Phase 1

What the Registry Record Tells You About NCT07686393

The ClinicalTrials.gov registry entry for NCT07686393 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which 11C-ARMI is the first listed.

NCT07686393 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07686393 about?

NCT07686393 is a clinical study titled "PET Imaging of Noradrenergic Transmission in the Brain". Background: Researchers have developed a new radioactive tracer (11C-ARMI). A tracer is a drug that attaches itself to other chemicals in the body and lights up so that the chemicals can be seen in imaging scans. The new tracer may be able to help them with many diseases, such as Alzheimer s diseas...

What is the current status of trial NCT07686393?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-07-15. Estimated completion is 2030-02-20.

What interventions are being tested in trial NCT07686393?

The interventions under investigation include: 11C-ARMI (DRUG).

Who is sponsoring clinical trial NCT07686393?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.